Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 1
2008 1
2010 4
2011 1
2012 4
2014 3
2015 1
2016 2
2017 1
2018 1
2019 3
2020 4
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A. Cuker A, et al. Among authors: steingo b. Mult Scler. 2020 Jan;26(1):48-56. doi: 10.1177/1352458518816612. Epub 2019 Feb 20. Mult Scler. 2020. PMID: 30785358 Free PMC article. Clinical Trial.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-word study is associated with disability progression.
Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Benedict RHB, Riolo J, Silva D, Dwyer MG; DeepGRAI Registry Study group. Zivadinov R, et al. J Neurol Neurosurg Psychiatry. 2022 Jul 28:jnnp-2022-329333. doi: 10.1136/jnnp-2022-329333. Online ahead of print. J Neurol Neurosurg Psychiatry. 2022. PMID: 35902228
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernández Ó, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS; CAMMS223, CAMMS03409, and TOPAZ Investigators. Steingo B, et al. J Neurol. 2020 Nov;267(11):3343-3353. doi: 10.1007/s00415-020-09983-1. Epub 2020 Jun 24. J Neurol. 2020. PMID: 32583052 Free PMC article.
Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R; Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators. Pioro EP, et al. Ann Neurol. 2010 Nov;68(5):693-702. doi: 10.1002/ana.22093. Ann Neurol. 2010. PMID: 20839238 Clinical Trial.
27 results